6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]
Published on
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
______________________________________________
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES
EXCHANGE ACT OF 1934
For the
month of October, 2009
Commission
File Number ________________
Novogen
Limited
(Translation
of registrant’s name into English)
140 Wicks
Road, North Ryde, NSW, Australia
(Address
of principal executive office)
___________________________________
Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form 20-F
x Form 40-F o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(l): o
Note:
Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form
6-K if submitted solely to provide an attached annual report to security
holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule lO1(b)(7): o
Note:
Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form 6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules of the home country exchange on
which the registrant’s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant’s security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.
Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes o No x
If “Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly
authorized.
Novogen
Limited
(Registrant)
/s/ Ron
Erratt
Ronald
Lea Erratt
Company
Secretary
Date
30 October, 2009
30
October 2009
The
Manager Companies
Australian
Securities Exchange
20 Bridge
Street
SYDNEY NSW 2000
Dear
Sir
Novogen
Annual Meeting
|
1.
|
Highlights
of Meeting
|
Highlights
of content presented at the Novogen Annual Meeting today covered its principal
areas of pharmaceutical development in treating diseases - particularly cancer
and wound healing - and included:
|
·
|
Novogen
continues with its business strategy of seeking out-licensing as its
technology progresses to later stages of
development;
|
|
·
|
the
Novogen Group is targeting two different pathways to overcome cancer: one
which dismantles the survival signalling mechanism of cancer cells
(phenoxodiol and triphendiol); and the other which inhibits the cancer
growth mechanism (NV-128);
|
|
·
|
the
possibility of these mechanisms working together has considerable
scientific and commercial
potential;
|
|
·
|
results
are expected in 2010 from the Phase III trial of phenoxodiol on ovarian
cancer patients;
|
|
·
|
triphendiol
progresses to further Phase I
trials;
|
|
·
|
NV-128
is advancing through preclinical
testing;
|
|
·
|
Glyc-101
is finalising a Phase IIa clinical trial in the US for wound
healing;
|
|
·
|
Novogen
now owns 114 patents, with 20 added in
FY09
|
|
·
|
at
September, 2009, Novogen Group cash reserves were $27
million.
|
|
2.
|
Results
of Meeting
|
In
accordance with Listing Rule 3.12.2 and 251 AA of the Corporations Act, details
of Annual Meeting resolutions and proxies received in respect of each resolution
are set out in the tables below.
Novogen
Directors note that, while a non-binding resolution to adopt the Remuneration
Report was also defeated, remuneration for the Board and executives was reduced
20 per cent in February, 2009.
Resolution
details are as follows:
|
Resolution
2
|
TO
ADOPT REMUNERATION REPORT
FOR
YEAR END 30 JUNE, 2009
|
|||
|
|
The
motion was not carried as an ordinary resolution on a poll
the
details of which are:
|
|||
|
|
For
|
Against
|
Abstain
|
|
|
9,525,010
|
40,181,591
|
508,972
|
||
|
Resolution
3
|
TO
RE-ELECT MR PHILIP A JOHNSON AS A DIRECTOR
|
|||
|
|
The
motion was carried as an ordinary resolution on a poll
the
details of which are:
|
|||
|
|
For
|
Against
|
Abstain
|
|
|
46,855,632
|
2,985,850
|
374,091
|
||
|
Resolution
4
|
TO
RE-ELECT PROF PAUL J NESTEL AO AS A DIRECTOR
|
|||
|
|
The
motion was carried as an ordinary resolution on a poll
the
details of which are:
|
|||
|
|
For
|
Against
|
Abstain
|
|
|
29,559,241
|
20,224,991
|
431,341
|
||
|
Resolution
5
|
TO
RE-ELECT MR WILLIAM D RUECKERT AS A DIRECTOR
|
|||
|
|
The
motion was carried as an ordinary resolution on a poll
the
details of which are:
|
|||
|
|
For
|
Against
|
Abstain
|
|
|
49,408,031
|
441,701
|
365,841
|
||
|
Resolution
6
|
The
resolution was withdrawn at the Annual General Meeting.
|
|||
|
|
||||
Yours
faithfully
/s/ Ron
Erratt
Ron
Erratt
Company
Secretary